pre-IPO PHARMA

COMPANY OVERVIEW

Cumulus Oncology Ltd (Edinburgh, UK) identifies, evaluates and where appropriate in-licenses novel oncology assets where future value inflections are foreseen. The licensing agreement for VER250840 comes after a rigorous due diligence conducted by the Cumulus Oncology team. This encompassed an in-depth analysis of the existing data package and an evaluation of future clinical development options in molecularly-selected groups of patients, showing specific DNA repair aberrations. Cumulus Oncology will partner with DNA repair specialist, LXRepair (Grenoble, France) and AI specialist, Intelligent Omics (Nottingham, UK) to define the optimal clinical setting for VER250840.


LOCATION

  • Edinburgh, , UK

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.cumulusoncology.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Feb 22, 2022

    Cumulus Oncology Secures £4.1m ($5.6m) Investment Led by Eos Advisory


    May 17, 2019

    Ligand Licenses VER250840 to Cumulus Oncology


    For More Press Releases


    Google Analytics Alternative